P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZED CLINICAL TRIALS (RCT)

P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZED CLINICAL TRIALS (RCT)

Bibliographic Details
Main Authors: H. Erba, D. Pollyea, M. Sekeres, G. Garcia-Manero, K. Seiter, I. DeGutis, P. Kiselev, A. McBride, E. Yu, G. Roboz
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000845224.64123.95

Internet

http://journals.lww.com/10.1097/01.HS9.0000845224.64123.95

Similar Items